NCT03395704 - A Study of LJPC-401 for the Treatment of Iron Overload in Adult Patients With Hereditary Hemochromatosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 29, 2017

Primary Completion Date

October 28, 2019

Study Completion Date

October 28, 2019

Conditions

Hereditary Hemochromatosis

Interventions

DRUG

LJPC-401

LJPC-401 subcutaneous injection, up to 20 mg weekly for 16 weeks. The minimum weekly dose will be 5 mg and the maximum weekly dose of LJPC-401 will be 20 mg.

DRUG

Placebo

0.9% Sodium Chloride Injection, USP, or equivalent

Trial Locations (31)

2145

Investigative Site, Westmead

2170

Investigative Site, Liverpool

3004

Investigative Site, Melbourne

4029

Investigative Site, Herston

4120

Investigative Site, Brisbane

6150

Investigative Site, Murdoch

10029

Investigative Site, New York

11030

Investigative Site, Manhasset

11733

Investigative Site, East Setauket

32204

Investigative Site, Jacksonville

33604

Investigative Site, Pessac

35033

Investigative Site, Rennes

39216

Investigative Site, Jackson

45000

Investigative Site, Orléans

46202

Investigative Site, Indianapolis

49519

Investigative Site, Wyoming

72117

Investigative Site, North Little Rock

75246

Investigative Site, Dallas

76104

Investigative Site, Fort Worth

77058

Investigative Site, Houston

78215

Investigative Site, San Antonio

90036

Investigative Site, Los Angeles

91942

Investigational Site, San Diego

92377

Investigative Site, Rialto

93140

Investigative Site, Bondy

94115

Investigative Site, San Francisco

94305

Investigative Site, Palo Alto

98104

Investigative Site, Seattle

BD9 6RJ

Investigative Site, Bradford

NE7 7DN

Investigative Site, Newcastle upon Tyne

PO6 3LY

Investigative Site, Portsmouth